A peptide links a small number of protein building blocks into a chain.
That tells you about the substance’s makeup. It does not decide whether it belongs in your care.
Approved medicine: a specific product and use
Federal drug oversight rests with the Food and Drug Administration (FDA).
An approval covers a particular product and intended use after the agency has reviewed them.
As of September 26, 2026, examples with FDA approval are Ozempic and Wegovy for semaglutide; for tirzepatide, they are Mounjaro and Zepbound.
- Ask which product and form the prescription would name.
- Ask what use it is approved for.
- Ask why it fits your health problem.
Compounding: making a medicine to order
A licensed doctor or pharmacist can prepare medicine to order, as an alternative to a drug company’s ready-made product.
Another kind of maker prepares batches at a place registered with the FDA, often for clinics and hospitals.
The FDA inspects that facility, which must comply with drug-factory quality rules.
Compounding can be legal, but the maker and ingredients must meet the rules (as of September 26, 2026).
A regular pharmacy needs a valid prescription that names the patient.
A raw ingredient must meet any existing official drug-quality standard. Without such a standard, a raw ingredient qualifies only if an FDA-approved drug uses it or the FDA’s allowed list includes it.
These are key checks, not the full set of rules. Ask the pharmacist why your exact medicine meets the requirements.
When an approved medicine cannot fill a particular need, compounding may fill that gap. The compounded preparation still has no FDA approval.
The FDA does not review these products for safety, quality or effectiveness before patients receive them.
- Ask what need the ready-made product cannot meet.
- Get the maker’s name, whether it is a pharmacy or another facility.
- Ask for the reason this exact preparation is allowed.
Research use: ask why it is being offered as treatment
A research label is not a prescription or evidence of approval.
The words “for research use only” give no permission to sell a product for human treatment. The FDA made that point in letters to sellers available as of September 26, 2026.
Those letters describe alleged wrongdoing by the sellers, according to the FDA. A letter is not a court’s decision.
- Pause if a research-labeled product is presented as treatment.
- Have the person assessing you spell out the product’s actual status.